MaxWell Biosciences
12 articles about MaxWell Biosciences
-
Maxwell Biosciences Names Two Biotech Leaders to Its Board of Directors
11/7/2022
Maxwell Biosciences announced the appointment of Kate McKinley and Douglas S. Boothe to its Board of Directors.
-
Maxwell Biosciences Announces In Vivo and In Vitro Data on CLAROMER™ Platform’s Ability to Treat and Prevent SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference
9/29/2022
Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced data on its CLAROMER drug discovery platform’s treatment and prevention of SARS-CoV-2, and potentially other respiratory viruses, through a series of pre-clinical in vitro and in vivo studies.
-
Maxwell Biosciences to Present Data on CLAROMERTM Platform’s Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference
9/22/2022
Maxwell Biosciences to Present Data on CLAROMER TM Platform’s Treatment and Prevention of SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference.
-
Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives
9/20/2022
Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced the appointments of three senior executives.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Maxwell Biosciences Announces the Appointment of Edward Rudnic, Ph.D., as Chief Operating Officer
4/21/2022
Maxwell Biosciences today announced the appointment of Edward Rudnic, Ph.D., as Chief Operating Officer, effective immediately.
-
Maxwell Biosciences Announces the CLAROMER™ Brand Biotech Therapeutics Platform as It Advances Toward Clinical Trials
5/18/2021
Maxwell Biosciences Announces the CLAROMER ™ Brand Biotech Therapeutics Platform as It Advances Toward Clinical Trials
-
Maxwell Biosciences Hires John Lord, Ph.D., as Vice President of Research and Development
5/6/2021
Maxwell Biosciences , the biotechnology company behind the CLAROMER™ brand anti-infective drug platform, today announced Dr. John Lord has been appointed vice president, Research and Development. Dr. Lord will serve on Maxwell Bioscience’s Executive Committee, reporting to chief executive officer Joshua McClure.
-
David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs
4/6/2021
Maxwell Biosciences, today announced it has secured a major investment from well-known pharmaceutical investor-entrepreneur and public service champion — David Evans Shaw.
-
New Research Findings Published in Pharmaceuticals Identify Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2
4/5/2021
New Research Findings Published in Pharmaceuticals Identify Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2 Antiviral peptoids are being developed by Maxwell Biosciences to treat Recurrent Herpes Labialis
-
New York University Professor of Chemistry Dr. Kent Kirshenbaum Named Chief Scientific Officer at Maxwell Biosciences
2/16/2021
Maxwell Biosciences develops antiviral drugs, designed to be Zero-Day Therapeutics, which have been shown in preclinical studies to destroy a broad spectrum of viruses including rapidly evolving Coronavirus strains, announced the appointment of prominent New York University faculty member Kent Kirshenbaum, Ph.D., as the company’s Chief Scientific Officer.
-
Maxwell Biosciences Appoints Sheetal Vali, Ph.D. as Director of Drug Development
2/16/2021
Maxwell Biosciences develops antiviral drugs, designed to be Zero-Day Therapeutics (ZDT) , which have been shown in preclinical studies to destroy a broad spectrum of viruses including rapidly evolving CoronaVirus strains, today announced the appointment of Sheetal Vali, Ph.D., as the company’s Director of Drug Development.